摘要
目的比较国产齐拉西酮片和氯丙嗪片治疗精神分裂症的临床疗效和安全性。方法将精神分裂症患者158例按性别、年龄、体质量、病程、分型配对随机分为齐拉西酮组和氯丙嗪组各79例。采用潘氏阳性与阴性症状量表(PANSS)和不良反应量表(TESS)评定疗效和不良反应。结果2周后齐拉西酮组PANSS总分下降显著大于氯丙嗪组。8周后齐拉西酮组阴性症状评分下降显著大于氯丙嗪组(P<0.05)。2组阳性症状、一般精神病理性症状和PANSS总分下降无显著性差异(P均>0.05)。齐拉西酮组不良反应少于氯丙嗪组。结论齐拉西酮对精神分裂症的疗效优于氯丙嗪,对阴性症状疗效优于氯丙嗪,且不良反应少。
Objective It is to compare the curative effect and safety between ziprasidone and chlorpromazine on schizophrenia. Methods 158 patients with schizophrenia were randomly divided into ziprasidone group and chlorpromazine group according to sex, age, body mass, course of disease and typing pairing. In each group there were 79 cases. Curative effect and untoward reaction of the two groups were assessed with the positive and negative syndrome scale （PANSS） and treatment emergent side effect scale （TESS）. Results After two weeks treatment, the total scores of PANSS in ziprasidone group were significantly higher than that in chlorpromazine group. After eight weeks treatment, the scores of negative symptoms in ziprasidone group were significantly higher than that in chlorpromazine group （P〈 0.05）. There was no significant difference on the scores of positive symptoms, the scores of general psychopathological symptoms and the total scores of PANSS between the two groups （P 〉0.05）. The untoward reaction in ziprasidone group was fewer than that in chlorpromazine group. Conclusion The curative effects of ziprasidone on schizophrenia and negative symptoms are more superior to chlorpromazine, and the untoward reaction of ziprasidone is fewer than chlorpromazine.
出处
《现代中西医结合杂志》
CAS
2008年第26期4056-4057,4064,共3页
Modern Journal of Integrated Traditional Chinese and Western Medicine
